[1]
|
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68:394-424. |
[2]
|
Zhang T, Yuan Q, Gu Z, et al. Advances of proteomics technologies for multidrug-resistant mechanisms[J]. Future Med Chem, 2019, 11:2573-2593. |
[3]
|
Taddia L, D'Arca D, Ferrari S, et al. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs:Novel strategies to overcome cancer chemoresistance[J]. Drug Resist Updat, 2015, 23:20-54. |
[4]
|
Takeya M, Komohara Y. Role of tumor-associated macrophages in human malignancies:friend or foe?[J]. Pathol Int, 2016, 66:491-505. |
[5]
|
Wang M, Zhao J, Zhang L, et al. Role of tumor microenvironment in tumorigenesis[J]. J Cancer, 2017, 8:761-773. |
[6]
|
Mills CD, Kincaid K, Alt JM, et al. M-1/M-2 macrophages and the Th1/Th2 paradigm[J]. J Immunol, 2000, 164:6166-6173. |
[7]
|
Zhu J, Zhi Q, Zhou BP, et al. The role of tumor associated macrophages in the tumor microenvironment:mechanism and functions[J].Anticancer Agents Med Chem, 2016, 16:1133-1141. |
[8]
|
Schultze JL, Schmidt SV. Molecular features of macrophage activation[J]. Semin Immunol, 2015, 27:416-423. |
[9]
|
Jeannin P, Paolini L, Adam C, et al. The roles of CSFs on the functional polarization of tumorassociated macrophages[J]. FEBS J, 2018, 285:680-699. |
[10]
|
Ostuni R, Kratochvill F, Murray PJ, et al. Macrophages and cancer:from mechanisms to therapeutic implications[J]. Trends Immunol, 2015, 36:229-239. |
[11]
|
Li X, Liu R, Su X, et al. Harnessing tumor-associated macrophages as aids for cancer immunotherapy[J]. Mol Cancer, 2019, 18:177. |
[12]
|
Wu K, Lin K, Li X, et al. Redefining tumor-associated Macrophage subpopulations and functions in the tumor microenvironment[J]. Front Immunol, 2020, 11:1731. |
[13]
|
Xue J, Schmidt SV, Sander J, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation[J]. Immunity, 2014, 40:274-288. |
[14]
|
Sica A, Mantovani A. Macrophage plasticity and polarization:in vivo veritas[J]. J Clin Invest, 2012, 122:787-795. |
[15]
|
Candido JB, Morton JP, Bailey P, et al. CSF1R(+) macrophages sustain pancreatic tumor growth through T cell Suppression and maintenance of key gene programs that define the squamous subtype[J]. Cell Rep, 2018, 23:1448-1460. |
[16]
|
Li M, Li M, Yang Y, et al. Remodeling tumor immune microenvironment via targeted blockade of PI3K-gamma and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy[J]. J Control Release, 2020, 321:23-35. |
[17]
|
Kowal J, Kornete M, Joyce JA. Re-education of macrophages as a therapeutic strategy in cancer[J]. Immunotherapy, 2019, 11:677-689. |
[18]
|
Sarode P, Zheng X, Giotopoulou GA, et al. Reprogramming of tumor-associated macrophages by targeting beta-catenin/FOSL2/ARID5A signaling:A potential treatment of lung cancer[J]. Sci Adv, 2020, 6:eaaz6105. |
[19]
|
Yin Y,Yao S,Hu Y,et al. The immune-microenvironment confers chemoresistance of colorectal cancer through macrophage-derived IL6[J]. Clin Cancer Res, 2017, 23:7375-7387. |
[20]
|
Li J, He K, Liu P, et al. Iron participated in breast cancer chemoresistance by reinforcing IL- 6 paracrine loop[J]. Biochem Biophys Res Commun, 2016, 475:154-160. |
[21]
|
Yang C, He L, He P, et al. Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway[J]. Med Oncol, 2015, 32:352. |
[22]
|
Wei C, Yang C, Wang S, et al. M2 macrophages confer resistance to 5-fluorouracil in colorectal cancer through the activation of CCL22/PI3K/AKT signaling[J]. Onco Targets Ther, 2019, 12:3051-3063. |
[23]
|
Yu S, Li Q, Yu Y, et al. Activated HIF1alpha of tumor cells promotes chemoresistance development via recruiting GDF15-producing tumor-associated macrophages in gastric cancer[J]. Cancer Immunol Immun, 2020, 69:1973-1987. |
[24]
|
Ireland L, Santos A, Ahmed MS, et al. Chemoresistance in pancreatic cancer is driven by stroma-derived insulin-like growth factors[J]. Cancer Res, 2016, 76:6851-6863. |
[25]
|
Zhang M, Zhang H, Tang F, et al. Doxorubicin resistance mediated by cytoplasmic macrophage colony-stimulating factor is associated with switch from apoptosis to autophagic cell death in MCF-7 breast cancer cells[J]. Exp Biol Med (Maywood), 2016, 241:2086-2093. |
[26]
|
Li D, Ji H, Niu X, et al. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer[J]. Cancer Sci, 2020, 111:47-58. |
[27]
|
He Z, Chen D, Wu J, et al. Yes associated protein 1 promotes resistance to 5-fluorouracil in gastric cancer by regulating GLUT3-dependent glycometabolism reprogramming of tumorassociated macrophages[J]. Arch Biochem Biophys, 2021, 702:108838. |
[28]
|
Yu S, Li Q, Wang Y, et al. Tumor-derived LIF promotes chemoresistance via activating tumorassociated macrophages in gastric cancers[J]. Exp Cell Res, 2021, 406:112734. |
[29]
|
Wang H, Wang L, Pan H, et al. Exosomes derived from macrophages enhance aerobic glycolysis and chemoresistance in lung cancer by stabilizing c-Myc via the inhibition of NEDD4L[J]. Front Cell Dev Biol, 2021, 8:231-246. |
[30]
|
Zhu X, Shen H, Yin X, et al. Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype[J]. J Exp Clin Cancer Res, 2019, 38:81. |
[31]
|
Stockmann C, Doedens A, Weidemann A, et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis[J]. Nature, 2008, 456:814-818. |
[32]
|
De Palma M, Lewis CE. Cancer:Macrophages limit chemotherapy[J]. Nature, 2011, 472:303-304. |
[33]
|
Li Y, Weng Y, Zhong L, et al. VEGFR3 inhibition chemosensitizes lung adenocarcinoma A549 cells in the tumor-associated macrophage microenvironment through upregulation of p53 and PTEN[J]. Oncol Rep, 2017, 38:2761-2773. |
[34]
|
Dalton HJ, Pradeep S, Mcguire M, et al. Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression[J]. Clin Cancer Res, 2017, 23:7034-7046. |
[35]
|
Bracci L, Schiavoni G, Sistigu A, et al. Immune-based mechanisms of cytotoxic chemotherapy:implications for the design of novel and rationale-based combined treatments against cancer[J]. Cell Death Differ, 2014, 21:15-25. |
[36]
|
Denardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy[J]. Cancer Discov, 2011, 1:54- 67. |
[37]
|
Baghdadi M, Wada H, Nakanishi S, et al. Chemotherapy-induced IL-34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells[J]. Cancer Res, 2016, 76:6030-6042. |
[38]
|
Larionova I, Cherdyntseva N, Liu T, et al. Interaction of tumor-associated macrophages and cancer chemotherapy[J]. Oncoimmunology, 2019, 8:1596004. |
[39]
|
Vahidian F, Duijf P, Safarzadeh E, et al. Interactions between cancer stem cells, immune system and some environmental components:Friends or foes?[J]. Immunol Lett, 2019, 208:19-29. |
[40]
|
Xiang T, Long H, He L, et al. Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer[J]. Oncogene, 2015, 34:165- 176. |
[41]
|
Mitchem JB, Brennan DJ, Knolhoff BL, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses[J]. Cancer Res, 2013, 73:1128-1141. |
[42]
|
Yang L, Dong Y, Li Y, et al. IL-10 derived from M2 macrophage promotes cancer stemness via JAK1/STAT1/NF-kappaB/Notch1 pathway in non-small cell lung cancer[J]. Int J Cancer, 2019, 145:1099-1110. |
[43]
|
Zhou W, Ke SQ, Huang Z, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth[J]. Nat Cell Biol, 2015, 17:170-182. |
[44]
|
Sainz BJ, Alcala S, Garcia E, et al. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment[J]. Gut, 2015, 64:1921- 1935. |
[45]
|
Nywening TM, Belt BA, Cullinan DR, et al. Targeting both tumour-associated CXCR2(+) neutrophils and CCR2(+) macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma[J]. Gut, 2018, 67:1112-1123. |
[46]
|
Lederman MM, Sieg SF. CCR5 and its ligands:a new axis of evil?[J]. Nat Immunol, 2007, 8:1283-1285. |
[47]
|
Gao D, Cazares LH, Fish EN. CCL5-CCR5 interactions modulate metabolic events during tumor onset to promote tumorigenesis[J]. BMC Cancer, 2017, 17:834. |
[48]
|
Halama N, Zoernig I, Berthel A, et al. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients[J]. Cancer cell, 2016, 29:587-601. |
[49]
|
Aldinucci D, Casagrande N. Inhibition of the CCL5/CCR5 axis against the progression of gastric cancer[J]. Int J Mol Sci, 2018, 19:1477. |
[50]
|
Huang H, Zepp M, Georges RB, et al. The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction[J]. Cancer Lett, 2020, 474:82-93. |
[51]
|
Lee C, Jeong H, Bae Y, et al. Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide[J]. J Immunother Cancer, 2019, 7:147. |
[52]
|
Hume DA, Macdonald KP. Therapeutic applications of macrophage colony-stimulating factor- 1(CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling[J]. Blood, 2012, 119:1810- 1820. |
[53]
|
Andersen MN, Etzerodt A, Graversen JH, et al. STAT3 inhibition specifically in human monocytes and macrophages by CD163-targeted corosolic acid-containing liposomes[J]. Cancer Immunol Immunother, 2019, 68:489-502. |
[54]
|
Rodell CB, Arlauckas SP, Cuccarese MF, et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy[J]. Nat Biomed Eng, 2018, 2:578-588. |
[55]
|
Tanei T, Leonard F, Liu X, et al. Redirecting transport of nanoparticle albumin-bound paclitaxel to macrophages enhances therapeutic efficacy against liver metastases[J]. Cancer Res, 2016, 76, 429-439. |
[56]
|
Choi J, Kim HY, Ju EJ, et al. Use of macrophages to deliver therapeutic and imaging contrast agents to tumors[J]. Biomaterials, 2012, 33:4195-4203. |